Skip to content

Advertisement

Trials

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

  • Jamie B. Oughton1Email author,
  • Laura Collett1,
  • Dena R. Howard1,
  • Anna Hockaday1,
  • Talha Munir2,
  • Kathryn McMahon1,
  • Lucy McParland1,
  • Claire Dimbleby1,
  • David Phillips1,
  • Andy C. Rawstron3 and
  • Peter Hillmen2
Trials201718:353

https://doi.org/10.1186/s13063-017-2107-0

Received: 19 January 2017

Accepted: 14 July 2017

Published: 26 July 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
19 Jan 2017 Submitted Original manuscript
14 Jun 2017 Reviewed Reviewer Report - Joel Dubin
29 Jun 2017 Author responded Author comments - Jamie Oughton
Resubmission - Version 2
29 Jun 2017 Submitted Manuscript version 2
14 Jul 2017 Reviewed Reviewer Report - Joel Dubin
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
14 Jul 2017 Editorially accepted
26 Jul 2017 Article published 10.1186/s13063-017-2107-0

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
(2)
St James’s Institute of Oncology, St James’s University Hospital, Leeds, UK
(3)
Haematological Malignancy Diagnostic Service, St James’s Institute of Oncology, St James’s University Hospital, Leeds, UK

Advertisement